Begin typing your search above and press return to search.

Bharat Biotech's Nasal Vaccine for Covid Launched

Each dose of this vaccine is expected to cost Rs 325 in government medical facilities and Rs 800 in private ones.

Bharat Biotechs Nasal Vaccine for Covid Launched

Sentinel Digital DeskBy : Sentinel Digital Desk

  |  28 Jan 2023 7:36 AM GMT

NEW DELHI: One of the premier pharma companies of the country which came into the limelight for its vaccine for Covid-19 named Covaxin has launched its latest nasal vaccine. Named iNCOVACC, this medication can be administered as a precautionary dose to all adults who have received the first two doses of either Covishield or Covaxin.

The Union Health Minister Mansukh Mandaviya and Union Science and Technology Minster Jitender Singh launched the country's first indigenously developed nasal vaccine for Covid on the occasion of the 74th Republic Day. Each dose of this vaccine is expected to cost Rs 325 in government medical facilities and Rs 800 in private ones.

According to the announcements, iNCOVACC will be available in government facilities in Delhi by the middle of the coming month. Speculations are that it will become available in other parts of the country by the month of March. The availability of the medication with private parties will depend on the booking made by individual medical facilities.

The iNCOVACC is a recombinant replication-deficient adenovirus vectored vaccine with perfusion stabilised spike protein. According to the company, this formula has passed through phase I, phase II and phase III clinical trials will successful results.

According to reports, a huge majority have taken the first and second doses of covid vaccination, but a very limited number of people have opted for the precautionary or booster dose of the medication. Most of the citizens had shown a lack of interest due to the needle pricks associated with the vaccination process. With the arrival of a painless method to administer the same, this number is expected to grow from the current around 27%.

Although the number of covid cases continues to come up in the country, it is still under safe limits. Following the increased infections in China and several other countries, India implemented random testing of passengers coming to the country from a few select nations.

Also Read: First Made-in-India intranasal Covid vaccine to be launched on Republic Day

Also Watch:

Next Story